Free Registration for Upcoming Webinar – Learn New Findings on siRNA Therapy

In the upcoming webinar, Creative Biolabs invites Dr. Markita Landry from the University of California to share her team’s research on Optimal Therapeutic Intervention Timepoints for siRNA-Based Huntington’s Disease Therapies.

New York, USA – October 22, 2021 – Gene editing, which used to sound like science fiction, has now become a reality. CRISPR/Cas, a Nobel Prize-winning precision genome editing tool, is unquestionably a game-changer in the field of gene therapy. Furthermore, a recent draft guidance from the US Food and Drug Administration (FDA) provides a clear structure for gene therapy researchers, potentially allowing for faster and more efficient early-stage clinical studies. Thanks to recent scientific advancements in clinical and commercial gene treatments, some previously incurable genetic disorders are now treatable.

As one of the leading life science service providers in the field of gene therapy development, Creative Biolabs has established the GTOnco™ platform to facilitate gene therapy-based immuno-oncology drugs development, and is dedicated to keeping up with the new technologies and research directions.

Now, Creative Biolabs has launched a free webinar series focusing on cutting-edge findings in gene therapy development and related technologies. The first live webinar will be held at 12:00 PM PST (3:00 PM EST) on November 23, 2021, with the theme Optimal Therapeutic Intervention Timepoints for siRNA-Based Huntington’s Disease Therapies.

The speaker of this webinar, Dr. Markita Landry, is an assistant professor in the Department of Chemical and Biomolecular Engineering at the University of California, Berkeley. Her team, Landry Lab, is composed of highly interdisciplinary scientists working at the intersection of nanomaterials research, near-infrared microscopy, and their application to the study of life.

In this webinar, Dr. Markita Landry is invited to discuss the innovative finding of her team, near-infrared catecholamine nanosensor (nIRCat), which can be used to image “hot spots” of dopamine activity in the striatum of R6/2 HD model mice, and how it advances siRNA therapies for Huntington’s disease as optimal therapeutic intervention timepoints. At the end of the webinar, a Q&A session is included to allow any questions from the audience.

“The ability of gene therapies to provide durable benefits to human health, justifies continued optimism and increasing efforts toward making these therapies part of our standard treatment armamentarium for human disease,” said Bella Smith, the Business Development Executive of Creative Biolabs, “and we are organizing free webinar to strengthen industry-academic communication, thus to promote the advances in gene therapy development.”

More information about the webinar series about gene therapy or services and products at Creative Biolabs can be found at

About Creative Biolabs

With years of experience in providing one-stop preclinical development service, Creative Biolabs has built a team of expertise of solid knowledge of gene therapy, and is fully competent in providing services for worldwide clients. The services include but are not limited to delivery vehicles development, gene editing for gene therapy, RNAi therapy development, safety and toxicology analysis, potency tests, and solutions of specific gene therapy development for diseases.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States